Healthcare Gilead disputes report that its drug flopped in leaked coronavirus trial Updated : April 24, 2020 07:46 AM IST The rate of death was similar at 13.9 percent for remdesivir versus 12.8 percent in the control group. Gilead shares closed down 4.3 percent after the data was inadvertently released. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.